

August 7, 2017

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company, at their meeting held on Monday, August 07, 2017, approved, acquisition of a Company in Bangladesh.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra
Company Secretary & Legal Head



Encl.: As above

Annexure I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	Name: Dr. Lal Path Labs Bangladesh (Pvt) Limited ("DLPLB") Turnover: As detailed in Point No. 10
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No, the transaction is not a related party transaction.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has decided to acquire 70% stake in DLPLB from its existing shareholders, with the objective of strengthening our presence in Bangladesh. Prior to our investment, DLPLB shall be acquiring the running diagnostics business of a sole-proprietorship firm in Dhaka, Bangladesh.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 6 month of Board approval
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Not Exceeding BDT 181.49 per share
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	70%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	DLPLB was incorporated on September 06, 2011 in Bangladesh. Turnover for the combined businesses of DLPLB and sole-proprietorship for the last three financial years (Amount in BDT Crores): 2015: BDT 3.6 2016: BDT 3.3 2017: BDT 3.1

